source
- Curium seeks FDA review of rival radioligand therapy to boost supply resilience against Novartis' PluvictoCurium is preparing to challenge Novartis' dominant prostate cancer radioligand therapy, Pluvicto, by entering discussions with the FDA about reviewing its own PSMA‑directed Lu‑177 candidate. Nova…
- Massachusetts biotech startups see funding gap widen as seed rounds shrink and Series A deals surgeA MassBio report shows that mature biotech firms in Massachusetts captured most of the venture capital in the first half of 2026, with nearly $3.5 billion invested, a 25% rise from the same period…